Skip to main content
Clinical Trials/NCT04388748
NCT04388748
Completed
Not Applicable

Randomized Controlled Trial of Stress Management and Resiliency Training for Depression (SMART-D) vs Treatment as Usual in the Treatment of Major Depression

Mayo Clinic3 sites in 1 country27 target enrollmentDecember 18, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depression
Sponsor
Mayo Clinic
Enrollment
27
Locations
3
Primary Endpoint
Change in severity of depression
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Researchers are trying to find out if a Stress Management and Resiliency Training (SMART-D) therapy will help with major depression treatment.

Registry
clinicaltrials.gov
Start Date
December 18, 2020
End Date
May 25, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ashok Seshadri

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Participants will be enrolled for this study from patients attending the Mayo Clinic Depression Center, Mayo Clinic Family Medicine clinics, Behavioral Health and Primary Care Clinic at Mayo Clinic Health System, Austin, MN, with a diagnosis of major depression, in partial or near remission with PHQ-9 scores ≤14
  • Participants will be required to be between 25 and 80 years old
  • Able to speak English
  • Able to provide written informed consent to participate in the study
  • Participants must have DSM-V diagnostic confirmation of major depressive disorder (MDD) (American Psychiatric Association 2013).
  • Participants will continue taking any prescribed medications from their clinical treatment team.
  • Participants with co-morbid secondary diagnoses of persistent depressive disorder and generalized anxiety disorders will be included in the study.
  • Participants must consent to audio recording of random group sessions which will be disclosed at the final study session.

Exclusion Criteria

  • Participants with bipolar disorder, active psychosis, active suicidal ideations, and active substance abuse meeting criteria for substance use disorders except nicotine, obsessive compulsive disorder, active panic disorder with agoraphobia or other phobic disorder, active posttraumatic stress disorder, active severe personality disorders will be excluded.
  • Pregnant women - because of time duration of the study.

Outcomes

Primary Outcomes

Change in severity of depression

Time Frame: Baseline, week 1, week 8, 3 months, 6 months

Measured using the 17 item Hamilton Depression Rating scale (HAM-D) where total scores are reported on a scale of 0 - 7 = Normal, 8 - 13 = Mild Depression, 14-18 = Moderate Depression, 19 - 22 = Severe Depression, \> 23 = Very Severe Depression

Change in patient health questionnaire depression assessment

Time Frame: Baseline, week 1, week 8, 3 months, 6 months

Measured using the patient health questionnaire (PHQ-9) where total scores are reported on a scale of 1-4 Minimal depression, 5-9 Mild depression, 10-14 Moderate depression, 15-19 Moderately severe depression, 20-27 Severe depression

Secondary Outcomes

  • Changed in perceived stress scale(1 week, 8 week, 3 month, 6 month)
  • Change in measures of resilience(1 week, 8 week, 3 month, 6 month)

Study Sites (3)

Loading locations...

Similar Trials